(Q38395423)

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update

21 January 2018

1 reference

Adenosine receptors as drug targets--what are the challenges?

21 January 2018

1 reference

Adenosine receptors and neurological disease: neuroprotection and neurodegeneration

21 January 2018

1 reference

Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility

21 January 2018

1 reference

Recent developments in adenosine receptor ligands and their potential as novel drugs

21 January 2018

1 reference

Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

21 January 2018

1 reference

A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease

21 January 2018

1 reference

Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration

21 January 2018

1 reference

Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.

21 January 2018

1 reference

Structure and function of adenosine receptors and their genes.

21 January 2018

1 reference

Aspects of the general biology of adenosine A2A signaling.

21 January 2018

1 reference

GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex

21 January 2018

1 reference

Structural and energetic effects of A2A adenosine receptor mutations on agonist and antagonist binding

21 January 2018

1 reference

The significance of G protein-coupled receptor crystallography for drug discovery

21 January 2018

1 reference

Substructure-based virtual screening for adenosine A2A receptor ligands

21 January 2018

1 reference

Computational prediction of alanine scanning and ligand binding energetics in G-protein coupled receptors

21 January 2018

1 reference

Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation

21 January 2018

1 reference

The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist

21 January 2018

1 reference

Structure of an agonist-bound human A2A adenosine receptor

21 January 2018

1 reference

Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine

21 January 2018

1 reference

Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions

21 January 2018

1 reference

Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation

21 January 2018

1 reference

Structure-based discovery of A2A adenosine receptor ligands

21 January 2018

1 reference

Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists

21 January 2018

1 reference

Adenosine A2A receptor as a drug discovery target

21 January 2018

1 reference

Cardiovascular adenosine receptors: expression, actions and interactions

21 January 2018

1 reference

Adenosine: setting the stage for plasticity

21 January 2018

1 reference

Adenosine A2A agonists in development for the treatment of inflammation

21 January 2018

1 reference

Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate

21 January 2018

1 reference

Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo

21 January 2018

1 reference

Adenosine A2A receptor signaling and golf assembly show a specific requirement for the gamma7 subtype in the striatum

21 January 2018

1 reference

Signalling from adenosine receptors to mitogen-activated protein kinases

21 January 2018

1 reference

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

21 January 2018

1 reference

Adenosine receptors as therapeutic targets

21 January 2018

1 reference

Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function

21 January 2018

1 reference

Production of functional recombinant G-protein coupled receptors for heteromerization studies

21 January 2018

1 reference

Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer

21 January 2018

1 reference

Heterodimeric adenosine receptors: a device to regulate neurotransmitter release.

21 January 2018

1 reference

Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation.

21 January 2018

1 reference

Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors

21 January 2018

1 reference

A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes.

21 January 2018

1 reference

G protein-coupled receptor heteromers as new targets for drug development

21 January 2018

1 reference

Adenosine receptors: expression, function and regulation

21 January 2018

1 reference

Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.

21 January 2018

1 reference

Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission.

21 January 2018

1 reference

L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies

21 January 2018

1 reference

Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease

21 January 2018

1 reference

Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function.

21 January 2018

1 reference

Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease

21 January 2018

1 reference

Rationally designed multi-targeted agents against neurodegenerative diseases

21 January 2018

1 reference

Polypharmacology: challenges and opportunities in drug discovery

21 January 2018

1 reference

The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's disease

21 January 2018

1 reference

Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes

21 January 2018

1 reference

Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells

21 January 2018

1 reference

Non-dopaminergic treatments for motor control in Parkinson's disease

21 January 2018

1 reference

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials

21 January 2018

1 reference

Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease

21 January 2018

1 reference

Adenosine receptor control of cognition in normal and disease

21 January 2018

1 reference

Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology

21 January 2018

1 reference

Crude caffeine reduces memory impairment and amyloid β(1-42) levels in an Alzheimer's mouse model

21 January 2018

1 reference

Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice

21 January 2018

1 reference

Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages

21 January 2018

1 reference

Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice

21 January 2018

1 reference

Region-specific neuroprotective effect of ZM 241385 towards glutamate uptake inhibition in cultured neurons.

21 January 2018

1 reference

Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice

21 January 2018

1 reference

A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.

21 January 2018

1 reference

Differential neuroprotection by A(1) receptor activation and A(2A) receptor inhibition following pilocarpine-induced status epilepticus.

21 January 2018

1 reference

Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction

21 January 2018

1 reference

The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat.

21 January 2018

1 reference

The protective effect of adenosine A2A receptor antagonism in cerebral ischemia.

21 January 2018

1 reference

Adenosine receptors in cerebral ischemia.

21 January 2018

1 reference

Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia

21 January 2018

1 reference

Adenosine A2A and A2B receptors are both required for adenosine A1 receptor-mediated cardioprotection

21 January 2018

1 reference

Abnormal calcium handling in atrial fibrillation is linked to up-regulation of adenosine A2A receptors.

21 January 2018

1 reference

Contribution of adenosine A(2A) and A(2B) receptors to ischemic coronary dilation: role of K(V) and K(ATP) channels

21 January 2018

1 reference

Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?

21 January 2018

1 reference

The role of adenosine receptors in rheumatoid arthritis.

21 January 2018

1 reference

Adenosine, adenosine receptors and glaucoma: an updated overview

21 January 2018

1 reference

Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3.

21 January 2018

1 reference

Pharmacological blockade of adenosine A2A receptors diminishes scarring

21 January 2018

1 reference

Adenosine A(2A) receptors promote collagen production by a Fli1- and CTGF-mediated mechanism.

21 January 2018

1 reference

Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis.

21 January 2018

1 reference

Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells.

21 January 2018

1 reference

Adenosine receptors as potential targets in melanoma

21 January 2018

1 reference

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

21 January 2018

1 reference

Adenosine A(2A) Receptor Antagonists and Parkinson's Disease

21 January 2018

1 reference

The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A2a selective adenosine receptor antagonist

21 January 2018

1 reference

Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued

21 January 2018

1 reference

Towards next generation adenosine A(2A) receptor antagonists

21 January 2018

1 reference

Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases

21 January 2018

1 reference

Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists

21 January 2018

1 reference

Recent developments in the field of A2A and A3 adenosine receptor antagonists

21 January 2018

1 reference

Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications

21 January 2018

1 reference

Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A₃ adenosine receptor antagonists

21 January 2018

1 reference

Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists

21 January 2018

1 reference

Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes

21 January 2018

1 reference

Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography

21 January 2018

1 reference

Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists

21 January 2018

1 reference

Development of [18F]-labeled pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidine (SCH442416) analogs for the imaging of cerebral adenosine A2A receptors with positron emission tomography

21 January 2018

1 reference

Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists

21 January 2018

1 reference

7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility

21 January 2018

1 reference

Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists

21 January 2018

1 reference

Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions

21 January 2018

1 reference

Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists

21 January 2018

1 reference

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

21 January 2018

1 reference

Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A(2A) receptor antagonists.

21 January 2018

1 reference

8-(Furan-2-yl)-3-phenethylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione as novel, selective and potent adenosine A(2A) receptor antagonist

21 January 2018

1 reference

Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.

21 January 2018

1 reference

Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists

21 January 2018

1 reference

In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.

21 January 2018

1 reference

Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists

21 January 2018

1 reference

JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease

21 January 2018

1 reference

1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases

21 January 2018

1 reference

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease

21 January 2018

1 reference

(E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists

21 January 2018

1 reference

2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor

21 January 2018

1 reference

Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists

21 January 2018

1 reference

Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists

21 January 2018

1 reference

Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2.

21 January 2018

1 reference

Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease

21 January 2018

1 reference

Design and evaluation of xanthine based adenosine receptor antagonists: potential hypoxia targeted immunotherapies

21 January 2018

1 reference

Novel 8-(p-substituted-phenyl/benzyl)xanthines with selectivity for the A2A adenosine receptor possess bronchospasmolytic activity

21 January 2018

1 reference

Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues

21 January 2018

1 reference

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

21 January 2018

1 reference

Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC)

21 January 2018

1 reference

Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors.

21 January 2018

1 reference

2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization

21 January 2018

1 reference

The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets

21 January 2018

1 reference

The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats

21 January 2018

1 reference

Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease

21 January 2018

1 reference

Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.

21 January 2018

1 reference

6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists

21 January 2018

1 reference

Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease

21 January 2018

1 reference

Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines

21 January 2018

1 reference

Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines

21 January 2018

1 reference

Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists

21 January 2018

1 reference

7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies

21 January 2018

1 reference

Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles

21 January 2018

1 reference

Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists

21 January 2018

1 reference

Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists

21 January 2018

1 reference

Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists

21 January 2018

1 reference

Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists

21 January 2018

1 reference

Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility

21 January 2018

1 reference

A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach

21 January 2018

1 reference

Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers

21 January 2018

1 reference

Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists

21 January 2018

1 reference

Scaffold Decoration at Positions 5 and 8 of 1,2,4-Triazolo[1,5-c]Pyrimidines to Explore the Antagonist Profiling on Adenosine Receptors: A Preliminary Structure–Activity Relationship Study

21 January 2018

1 reference

Substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists

21 January 2018

1 reference

Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives

21 January 2018

1 reference

Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives

21 January 2018

1 reference

Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists

21 January 2018

1 reference

Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives

21 January 2018

1 reference

Synthetic studies on selective adenosine A2A receptor antagonists. Part II: synthesis and structure-activity relationships of novel benzofuran derivatives

21 January 2018

1 reference

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

21 January 2018

1 reference

Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists.

21 January 2018

1 reference

Benzothiazinones: a novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives

21 January 2018

1 reference

Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones

21 January 2018

1 reference

Identification of novel adenosine A(2A) receptor antagonists by virtual screening.

21 January 2018

1 reference

2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists

21 January 2018

1 reference

Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy

21 January 2018

1 reference

2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents

21 January 2018

1 reference

2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships

21 January 2018

1 reference

2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability

21 January 2018

1 reference

Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists

21 January 2018

1 reference

2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A(2A) antagonists with improved solubility and metabolic stability

21 January 2018

1 reference

Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease

21 January 2018

1 reference

N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy

21 January 2018

1 reference

Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists

21 January 2018

1 reference

Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease

21 January 2018

1 reference

Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides

21 January 2018

1 reference

Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides

21 January 2018

1 reference

Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists

21 January 2018

1 reference

Discovery of 1,2,4-Triazine Derivatives as Adenosine A 2A Antagonists using Structure Based Drug Design

21 January 2018

1 reference

Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition

21 January 2018

1 reference

Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect

21 January 2018

1 reference

A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs

21 January 2018

1 reference

Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.

21 January 2018

1 reference

The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade

21 January 2018

1 reference

Emerging therapies for Parkinson's disease: from bench to bedside.

21 January 2018

1 reference

Epidemiology of Parkinson's disease

21 January 2018

1 reference

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

21 January 2018

1 reference

Istradefylline: first global approval

21 January 2018

1 reference

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

21 January 2018

1 reference

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

21 January 2018

1 reference

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

21 January 2018

1 reference

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

21 January 2018

1 reference

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results

21 January 2018

1 reference

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

21 January 2018

1 reference

Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.

21 January 2018

1 reference

Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats

21 January 2018

1 reference

ST 1535: a preferential A2A adenosine receptor antagonist

21 January 2018

1 reference

Future treatments for Parkinson's disease: surfing the PD pipeline

21 January 2018

1 reference

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

21 January 2018

1 reference

An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers

21 January 2018

1 reference

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects

21 January 2018

1 reference

Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation

21 January 2018

1 reference

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

21 January 2018

1 reference

Adenosine A(2A) receptor antagonists as Positron Emission Tomography (PET) tracers

21 January 2018

1 reference

Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys

21 January 2018

1 reference

Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease

21 January 2018

1 reference

Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Template: Organic and Medicinal Chemistry Approach

21 January 2018

1 reference

Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists

21 January 2018

1 reference